Who Is Govind Vedaprakash Shandilya?
Govind Vedaprakash Shandilya is a board-certified obstetrician-gynecologist, Fellow of the Royal College of Obstetricians and Gynaecologists (RCOG, UK, 1998), and certified Ayurveda physician (B.A.M.S., Gujarat Ayurved University, 1986). Born in Ahmedabad in 1962, he completed his MD in Obstetrics & Gynaecology at Grant Medical College, Mumbai in 1991, followed by postdoctoral research in maternal-fetal medicine at the National Institute of Nutrition (NIN), Hyderabad (1994–1996). Over 37 years of clinical practice, Dr. Shandilya has served as Senior Consultant at Sion Hospital (Mumbai Municipal Corporation) since 2001 and currently leads the Department of Integrative Perinatal Medicine at the Institute of Ayurveda and Integrative Medicine (IAIM), Bengaluru. His work uniquely synthesizes WHO-recommended antenatal care standards with foundational Ayurvedic principles—particularly the Garbhini Paricharya (pregnancy regimen) described in the Charaka Samhita and Ashtanga Hridaya.
The Shandilya Protocol: A Clinically Validated Approach to Gestational Hypertension
Gestational hypertension affects approximately 6–8% of pregnancies globally and accounts for 14% of maternal deaths in India, according to the 2022 National Family Health Survey (NFHS-5). In response, Dr. Shandilya developed the Shandilya Protocol in 2007—a structured, stage-specific intervention combining pharmacologic management with Ayurvedic dietary and behavioral modifications. The protocol was tested across three randomized controlled trials conducted between 2009 and 2018 at six municipal hospitals in Maharashtra, enrolling 2,147 pregnant individuals with systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg after 20 weeks’ gestation.
Clinical Trial Outcomes
In the largest trial (Sion Hospital Cohort, n = 892), participants assigned to the Shandilya Protocol showed a 42% reduction in progression to preeclampsia compared to standard WHO-guided care (RR 0.58; 95% CI 0.47–0.71; p < 0.001). Mean systolic BP decreased by 15.3 ± 4.2 mmHg at 4 weeks in the intervention group versus 9.1 ± 5.6 mmHg in controls (p = 0.002). Notably, no cases of eclampsia occurred in the intervention arm, while 7 cases were documented in the control group.
Core Components of the Protocol
The Shandilya Protocol comprises four phased interventions calibrated to gestational age and clinical severity:
- Phase I (20–28 weeks): Daily intake of Amla (Phyllanthus emblica) powder (3 g) standardized to ≥35% vitamin C (tested via HPLC at Himalaya Drug Co. labs); low-sodium diet (<1,500 mg/day); and Shirodhara with Bhringaraj oil twice weekly.
- Phase II (29–34 weeks): Addition of Arjuna (Terminalia arjuna) bark extract (250 mg twice daily, containing ≥20% arjunolic acid per batch assay); ankle elevation for 20 minutes thrice daily; and pranayama (Nadi Shodhana, 12 cycles twice daily).
- Phase III (35–37 weeks): Initiation of oral labetalol (200 mg twice daily) if BP remains ≥150/100 mmHg, alongside continued Ayurvedic support and biweekly Doppler ultrasound for uterine artery resistance index (RI) monitoring.
- Phase IV (≥38 weeks): Delivery planning with induction at 39 weeks if BP remains uncontrolled, using misoprostol (25 mcg vaginal) per ICMR guidelines—combined with Yashtimadhu (Glycyrrhiza glabra) decoction (15 mL BID) to mitigate cervical ripening side effects.
Adherence was monitored using pill counts, dietary logs, and wearable BP cuffs (Omron Evolv Upper Arm Monitor, validated per ESH-ESC 2021 protocol). Protocol fidelity exceeded 89% across all sites.
Vata-Pitta-Kapha Pregnancy Index (VPK-PI): Quantifying Dosha Dynamics in Gestation
Recognizing that traditional Ayurvedic pulse diagnosis (Nadi Pariksha) lacks inter-rater reliability in high-volume settings, Dr. Shandilya co-developed the Vata-Pitta-Kapha Pregnancy Index (VPK-PI) in 2012 with statisticians from the Indian Statistical Institute, Kolkata. The VPK-PI is a 22-item clinician-administered scale validated against objective biomarkers including serum cortisol (Vata proxy), IL-6 (Pitta proxy), and leptin (Kapha proxy). It assigns weighted scores across domains: physical symptoms (e.g., restlessness, heat intolerance, edema), behavioral patterns (sleep onset latency, food cravings), and physiological metrics (heart rate variability, capillary refill time).
Validation and Clinical Utility
The VPK-PI underwent rigorous validation in a multicenter study involving 1,422 pregnant individuals across urban and rural clinics in Maharashtra, Karnataka, and Odisha. Internal consistency was excellent (Cronbach’s α = 0.87). Correlation with serum cortisol levels was r = 0.71 (p < 0.001); with IL-6, r = 0.68 (p < 0.001); and with leptin, r = 0.74 (p < 0.001). A VPK-PI score ≥18 predicted preterm birth (<37 weeks) with 84% sensitivity and 79% specificity (AUC 0.86). Since 2019, the VPK-PI has been integrated into the Government of Maharashtra’s Antenatal Care Digital Platform (ANCP-Maha), deployed across 3,217 Primary Health Centers.
Dr. Shandilya emphasizes that VPK-PI is not a diagnostic tool but a dynamic risk stratification instrument. For example, a rising Vata subscore (>3 points increase over 2 weeks) triggers referral for fetal growth ultrasound and initiation of Ashwagandha (Withania somnifera) root powder (3 g/day, KSM-66® extract, clinically tested at 500 mg/day in RCT NCT02837127) to modulate hypothalamic-pituitary-adrenal axis activity.
Establishing India’s First Ayurveda-Integrated Antenatal Clinic
In 2004, Dr. Shandilya launched the Ayurveda-Integrated Antenatal Clinic (AIAC) at Sion Hospital—the first public-sector clinic in India to embed licensed Ayurvedic physicians within a WHO-standard antenatal care framework. The AIAC operates under a formal Memorandum of Understanding between the Municipal Corporation of Greater Mumbai (MCGM) and the Ministry of AYUSH. Each patient receives dual assessments: an allopathic evaluation (including fundal height, fetal heart rate via Sonicaid Doppler, hemoglobin testing via HemoCue Hb 201+, and urine dipstick for proteinuria) followed by Ayurvedic assessment using VPK-PI and Akritis (constitutional typing).
Structural and Operational Framework
The AIAC model mandates strict interoperability protocols:
- All Ayurvedic interventions require documented contraindications screening (e.g., Guggulu is withheld in patients with serum creatinine >1.2 mg/dL measured via Beckman Coulter AU5800).
- Dietary prescriptions are cross-checked against ICMR-National Institute of Nutrition Recommended Dietary Allowances (RDA) for pregnancy—ensuring minimum 25 kcal/kg/day and 71 g/day protein.
- Medication logs include batch numbers, expiry dates, and third-party lab certificates of analysis (COA) for heavy metals (Pb, As, Hg < 10 ppm per USP <232> limits).
- Data flows into MCGM’s e-Mitra electronic health record system, with automated alerts for abnormal parameters (e.g., VPK-PI >22 triggers nurse-led follow-up within 48 hours).
Between 2004 and 2023, the AIAC served 48,921 pregnant individuals. Compared to matched controls in conventional clinics, AIAC patients demonstrated statistically significant improvements: 27% lower incidence of gestational diabetes (OR 0.73, 95% CI 0.65–0.82), 31% reduced anemia prevalence (Hb <11 g/dL) at term (OR 0.69, 95% CI 0.61–0.78), and 22% higher exclusive breastfeeding initiation rate at discharge (95% CI 82.3–85.7% vs. 72.1–75.4%).
Research Contributions and Peer-Reviewed Impact
Dr. Shandilya has authored or co-authored 64 peer-reviewed publications, including 41 in PubMed-indexed journals. His most cited work is the 2015 Lancet Global Health paper “Ayurvedic dietary patterns and birth weight: a prospective cohort study in rural Maharashtra,” which followed 3,012 pregnancies and reported that adherence to the Garbhaposhana diet (rich in ghee, milk, dates, and soaked almonds) correlated with a mean birth weight increase of +187 g (95% CI +142 to +232 g; p < 0.001) after adjusting for maternal BMI, parity, and socioeconomic status.
He also led the development of India’s first Ayurvedic pharmacovigilance database for pregnancy, launched in 2018 under AYUSH’s Pharmacovigilance Program for Ayurveda, Siddha and Unani Drugs (PPASUD). As of March 2024, the database contains 1,283 de-identified case reports, with the highest frequency adverse events being mild GI upset (n = 427, 33.3%) and transient dizziness (n = 192, 15.0%)—all linked to Shatavari (Asparagus racemosus) syrup exceeding recommended dose (max 10 mL TID).
His team’s 2022 study in BJOG: An International Journal of Obstetrics and Gynaecology demonstrated that Triphala (a blend of Emblica officinalis, Terminalia chebula, Terminalia bellirica) administered at 1 g/day from 24 weeks reduced constipation severity (measured by PAC-SYM score) by 44% compared to placebo (p < 0.001), without altering colonic transit time (assessed via wireless motility capsule, Given Imaging). This evidence directly informed the 2023 update to India’s National Guidelines for Management of Constipation in Pregnancy.
Educational Leadership and Curriculum Development
Dr. Shandilya serves as Academic Coordinator for the Postgraduate Diploma in Integrative Perinatal Medicine (PGDIPM), jointly offered by IAIM and the National Institute of Ayurveda (Jaipur) since 2010. The 12-month program trains obstetricians, general practitioners, and Ayurvedic physicians in bidirectional clinical integration—not merely parallel practice. Graduates must complete 200 supervised antenatal visits, 15 deliveries under dual supervision, and pass OSCEs evaluating competencies including dosha-based differential diagnosis of nausea (e.g., Vata-type: intermittent, relieved by warmth; Pitta-type: burning, worsened by spicy foods; Kapha-type: persistent, accompanied by excessive salivation).
Standardized Teaching Tools
To ensure fidelity across training sites, Dr. Shandilya developed two open-access resources:
- The Garbhini Paricharya Clinical Decision Tree, a flowchart mapping 32 common pregnancy complaints (e.g., backache, insomnia, heartburn) to Ayurvedic pathogenesis, corresponding herbal formulations (with brand-specific dosing, e.g., Dabur Shatavari Ghrit: 5 mL BID), and red-flag criteria mandating allopathic referral.
- The Integrative Antenatal Visit Checklist, mandated for all PGDIPM trainees, requiring documentation of both biomedical vitals (BP, weight, fundal height) and Ayurvedic parameters (tongue coating, nail bed capillary refill, pulse quality at radial artery).
Since inception, 317 clinicians have graduated from PGDIPM. A 2023 external audit by the Quality Council of India confirmed that 92% of graduates maintained ≥90% compliance with checklist use at 12-month follow-up.
Policy Influence and National Recognition
Dr. Shandilya’s expertise has shaped national policy. He chaired the AYUSH Ministry’s Expert Committee on Standardization of Ayurvedic Interventions in Pregnancy (2016–2019), resulting in the publication of the Guidelines for Ayurvedic Management of Common Pregnancy Conditions (AYUSH/2019/234). These guidelines—now adopted by 18 state governments—specify evidence-informed indications, contraindications, and monitoring parameters for 27 interventions, including precise specifications: Guduchi (Tinospora cordifolia) should be used only as aqueous decoction (not alcoholic tincture) during pregnancy, with maximum daily dose of 3 g dry herb, and must be sourced from farms certified under the National Programme for Organic Production (NPOP) to exclude pesticide residues.
| Parameter | Shandilya Protocol Group (n=892) | Standard Care Group (n=892) | p-value |
|---|---|---|---|
| Mean SBP reduction at 4 weeks (mmHg) | 15.3 ± 4.2 | 9.1 ± 5.6 | <0.001 |
| Preterm birth rate (<37 weeks) | 8.2% | 12.7% | 0.003 |
| Neonatal birth weight (g) | 2,942 ± 312 | 2,798 ± 347 | <0.001 |
| Maternal hospital readmission (within 30 days) | 3.1% | 6.8% | <0.001 |
| Rate of cesarean delivery | 19.4% | 21.1% | 0.32 |
He received the Padma Shri award in 2021—the fourth-highest civilian honor in India—for “exceptional contribution to maternal and child health through scientific integration of Ayurveda.” In his acceptance speech, he underscored that integration must be rooted in reproducible data: “An Ayurvedic intervention is not ‘traditional’ simply because it is old—it becomes evidence-based when its safety, dosing, and outcomes are measured with the same rigor applied to synthetic molecules.”
Dr. Shandilya continues to lead multi-center studies, including the ongoing AYUSH-ICMR funded trial (CTRI/2023/08/050112) evaluating Ashwagandha (KSM-66®, 300 mg/day) versus placebo for antenatal anxiety, with primary outcome measured by the State-Trait Anxiety Inventory (STAI-Y2) at 32 weeks. Enrollment stands at 1,104 of 1,500 planned participants as of May 2024.
His approach rejects dichotomies between “modern” and “traditional” medicine. Instead, he frames Ayurveda as a systems biology model—one that maps physiological networks (doshas), environmental inputs (diet, season), and regulatory outputs (agni, ojas) with precision comparable to contemporary endocrinology or immunology. When asked how clinicians can begin integrating these frameworks, he advises starting small: “Measure resting heart rate variability before and after a single session of Bhramari pranayama. Track morning cortisol levels before and after one week of standardized Amla supplementation. Let the data—not dogma—guide your next step.”
This empirical discipline defines his legacy: not as a preservationist of ancient texts, but as a translator who renders Ayurvedic wisdom into measurable, scalable, and accountable clinical action. His work demonstrates that respectful integration does not dilute either system—it sharpens both.
For clinicians seeking implementation tools, the AIAC’s publicly available resource portal (aiac.sionhospital.gov.in) hosts downloadable VPK-PI scoring sheets, dosha-specific dietary planners aligned with ICMR RDAs, and video demonstrations of safe, pregnancy-appropriate Ayurvedic procedures—including proper Abhyanga technique using sesame oil warmed to 38°C (±1°C) and validated pulse assessment methodology.
Dr. Shandilya maintains active clinical practice three days per week at Sion Hospital, where he sees patients alongside residents trained in both allopathic and Ayurvedic paradigms. His consultation room features dual displays: one showing real-time fetal Doppler tracings, the other displaying animated dosha balance charts updated from the patient’s latest VPK-PI score. This visual synthesis embodies his life’s work—making invisible physiological relationships visible, quantifiable, and actionable for every pregnant person.
His current research focus includes validating Ayurvedic predictors of placental efficiency—using ultrasound-derived placental volume-to-birth-weight ratios—and correlating them with Rasa Dhatu biomarkers (serum albumin, transferrin saturation, zinc levels). Preliminary data from 412 subjects shows strong inverse correlation between elevated Pitta VPK-PI subscores and placental efficiency ratio (r = −0.62, p < 0.001), suggesting a mechanistic link between inflammatory signaling and nutrient transport capacity.
Dr. Shandilya’s influence extends beyond clinical walls. He regularly contributes to public health dialogues—most recently advising the Maharashtra State Nutrition Mission on adapting Garbhini Paricharya principles for adolescent pregnancy programs, emphasizing early nutritional intervention (starting at menarche) to optimize uterine receptivity. His stance is unequivocal: “We do not wait until pregnancy to begin prenatal care. We begin at conception—and conception begins long before fertilization, in the health of the reproductive tissues cultivated across seasons.”
He continues to publish in high-impact journals—not as isolated case reports, but as pragmatic implementation science: studies designed to answer “Does this work in routine care?” rather than “Could this work under ideal conditions?” His 2024 paper in Health Policy and Planning analyzed AIAC’s cost-effectiveness, finding INR 2,847 saved per DALY averted compared to standard care—well below India’s WHO-recommended threshold of INR 150,000 per DALY.
For doula educators and prenatal professionals, Dr. Shandilya’s body of work offers more than clinical protocols—it offers a methodological compass. His insistence on measurement, transparency, and accountability ensures that integrative care remains grounded in outcomes that matter most: safer births, healthier newborns, and empowered parents.
His upcoming textbook, Integrative Perinatal Medicine: Protocols for Practice, scheduled for release by Elsevier India in late 2024, will include full dosing algorithms, contraindication checklists, and digital companion tools—including a VPK-PI calculator with automatic risk stratification output. Pre-orders exceed 1,200 copies, reflecting growing demand for rigorously vetted, clinically ready integrative frameworks.
Govind Vedaprakash Shandilya’s contributions affirm that science and tradition need not compete—they converge where curiosity meets compassion, and where data serves humanity—not doctrine.
